Clinical Study Links CBD Use with Liver Damage
A recently published study by the FDA showed elevated liver enzymes in some trial participants with daily use of CBD.
Many CBD products readily available to consumers are unregulated. CBD use has increased in the U.S. as more products become available.
MedpageToday reports that a small percentage (5.6%) of daily CBD users exhibited significant liver enzyme elevations in a study published in JAMA Internal Medicine in July 2025.
The implications of these findings suggest that further research is needed to determine the safety of these products. In the study, liver enzymes returned to normal within 1-2 weeks of discontinuing CBD. Clinicians should consider screening patients with elevated liver enzymes for CBD use.
This article falls under Clinical/Patient Safety in the Enterprise Risk Management (ERM) risk domains.
Clinical/Patient Safety
Risks associated with the delivery of care to patients, residents and other health care customers. Clinical risks include failure to follow evidence-based practice, medication errors, hospital acquired conditions (HAC), serious safety events (SSE), health care equity, opportunities to improve safety within the care environments, and others.